首頁 > 市場調查報告書 > 醫療設備

心血管設備

市場調查報告書

商品編碼

1373387

全球心室輔助裝置市場 - 2023-2030

Global Ventricular Assist Devices Market - 2023-2030

出版日期: 2023年10月18日 | 出版商:

DataM Intelligence | 英文 185 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

心室輔助裝置 (VAD) 是一種機械泵，用於支持心臟衰弱或衰竭患者的心臟功能和血流。它用於部分或完全取代衰竭心臟的功能。

VAD 旨在輔助右心室 (RVAD) 或左心室 (LVAD) 或輔助雙心室 (BiVAD)。透過減輕心臟的工作負荷，VAD 可以延長生命並改善疲勞和呼吸困難等症狀。

市場動態：促進因素與限制因素

增加心臟病和心臟衰竭的負擔

心臟病數量的增加和心臟衰竭負擔的增加預計將推動市場成長。這些因素增加了對心室輔助裝置的需求。此外，技術進步的增加和設備批准的增加也有望推動市場。

例如，根據 2022 年發布的報告，估計全球有 2,600 萬人患有心臟衰竭，並導致全球醫療費用增加。心臟衰竭仍然是世界高度流行的疾病，發病率和死亡率很高。

此外，根據《美國心臟病學會雜誌》發表的報告，高收縮壓仍然是全球心血管疾病過早死亡的主要可改變危險因素，2021 年心血管疾病死亡人數約為1,080 萬人，總體死亡人數為1130 萬人。與缺血性心臟病和中風相關的死亡尤其相關。因此，預計上述因素將在預測期內推動市場成長。

克制

設備和程序成本高

使用心室輔助裝置所涉及的高成本和嚴重併發症（如血栓和出血）等因素限制了全球心室輔助裝置市場的成長。

The increase in the number of cardiac diseases and the increase in the heart failure burden is expected to drive the market growth. These factors increase the demand for ventricular assist devices. Additionally, the increase in technological advancements and the increase in the approvals of the devices are also expected to drive the market.

For instance, according to the report published in 2022, it is estimated that heart failure has an estimated prevalence of 26 million people worldwide and contributes to increased healthcare costs worldwide. Heart failure remains a highly prevalent disorder worldwide with a high morbidity and mortality rate.

Additionally, according to the report published in the Journal of the American College of Cardiology, high systolic blood pressure remains the leading modifiable risk factor globally for attributable premature cardiovascular deaths, which was about 10.8 million cardiovascular deaths and 11.3 million deaths overall in 2021, and has been particularly linked to ischemic heart disease and stroke-related deaths. Thus, the above factors are expected to drive the market growth in the forecast period.

Restraint

High costs of devices and the procedures

Factors such as high cost and serious complications involved with the usage of ventricular assist devices such as blood clots and bleeding, are restricting the global ventricular assist devices market growth.

Segment Analysis

The global ventricular assist devices market is segmented based on product type, design application, end-user and region.

Left ventricular assist device segment accounted for 48.3% of the market share

The left ventricular assist devices segment is expected to hold a dominant share in the global ventricular assist devices market because of the advantages of the LAVD over other types. The left ventricular assist device (LVAD) is the most common device applied to a defective heart (it is sufficient in most cases.

Left Ventricular Assist Devices (LVADs) are mechanical devices that are implanted in patients with advanced heart failure, help the heart pump blood more effectively, and could benefit patients with advanced heart failure as they await donors. They improve the function of the kidneys, liver, brain, and other organs by increasing blood flow to the body.

Left Ventricular Assist Device (LVAD) helps the left side of the heart pump blood to a large blood vessel called the aorta and to the rest of the body.

Additionally, the increase in the number of heart diseases, an increase in the geriatric population, and the increase in the number of launches of the devices are expected to drive the segment's growth. Thus, the above factors are expected to hold a significant position in the market share.

Geographical Analysis

North America is expected to hold a significant position in the global ventricular assist devices market share

North America holds a dominant share in the ventricular assist devices market share owing to technological advancements and, an increase in the burden of heart diseases and is expected to continue throughout the forecast period.

For instance, according to the report by CDC in 2021, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. One person dies every 33 seconds in the United States from cardiovascular disease and about 695,000 people in the United States died from heart disease in 2021.

According to the report by the Centers for Disease Control & Prevention (CDC) in 2023, it is estimated that about 805,000 people in the United States have a heart attack every year. Among these, 605,000 are a first heart attack and 200,000 happen to people who have already had a heart attack.

Thus, an increase in the burden of heart diseases, and also increase in the advancements in the region, and the presence of major companies in the region are expected to drive market growth in the region.

COVID-19 Impact Analysis:

The COVID-19 has impacted the ventricular assist devices market negatively. The reduction in the number of cardiovascular surgeries and the closure of hospitals during the period of lockdown has impacted the market growth. People refused to visit hospitals for treatment procedures because of the spread of the virus. Thus, COVID-19 has reduced the growth of the market.

Competitive Landscape

The leading companies with a significant market share include: Abbott Laboratories, Abiomed Inc, Berlin Heart GmbH, Medtronic Plc, Jarvik Heart, Inc., EVAHEART, INC., Cirtec, CorWave SA, Calon Cardio-Technology Ltd, and Teleflex Incorporated.

Key Developments

On June 20, 2023, CorWave declared that its Series C round has brought in a total of $64 million to fund entry into clinical trials and initial manufacturing of its wave membrane LVAD.
On January 6, 2022, the IIT Kanpur has forayed into the field of medical technology with its ambition of creating the world's most advanced Left Ventricular Assist Device (LVAD).

Why Purchase the Report?

To visualize the global ventricular assist devices market segmentation based on product type, design, application, end-user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of ventricular assist devices market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global ventricular assist devices market report would provide approximately 69 tables, 68 figures, and 185 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Design
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing cardiac disease and heart failure burden
  - 4.1.1.2.
- 4.1.2. Restraints
  - 4.1.2.1. High costs of devices and the procedures
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Left Ventricular Assist Device *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Right Ventricular Assist Device
7.4. Biventricular Assist Device

8. By Design

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
- 8.1.2. Market Attractiveness Index, By Design
8.2. Implantable Ventricular Assist Devices *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Transcutaneous Ventricular Assist Devices

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Bridge to Candidacy Therapy *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Bridge to Transplant Therapy
9.4. Bridge to Recovery Therapy
9.5. Destination Therapy

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Specialty Clinics
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Abbott Laboratories *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Abiomed Inc
13.3. Berlin Heart GmbH
13.4. Medtronic Plc
13.5. Jarvik Heart, Inc
13.6. EVAHEART, INC.
13.7. Cirtec
13.8. CorWave SA
13.9. Calon Cardio-Technology Ltd
13.10. Teleflex Incorporated.